Sanofi launches AI-powered rare disease pre-diagnosis tool in India

In a country where a patient with a rare disease waits too long before receiving a correct diagnosis, Sanofi has announced the India launch of AccelRare®, an artificial intelligence (AI)-powered digital pre-diagnosis tool designed to transform the way healthcare professionals diagnose rare diseases; and dramatically reduce the time it takes for patients to access life changing treatment.

The launch marks a defining moment in Sanofi's ambition to become the first pharmaceutical company powered by artificial intelligence at scale, deploying AI not just in laboratories and clinical trials, but directly at the point of care, where the distance between a patient and a diagnosis can mean years of suffering.

Co-developed and validated by 67 rare disease experts across 13 rare disease networks, AccelRare® is built on MedVir™, which is certified as a Class I medical device in Europe.

In India, AccelRare® is approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device. It is available free of charge, requires no registration, is highly secure and collects no patient identification data, making it as accessible as it is powerful.

Dr Mayur Shah, Head of Rare Diseases Business, Sanofi India said, "Behind the word 'rare' lies a staggering reality. An estimated 72-96 million people in India are living with a rare disease2, and by the time many receive an accurate diagnosis, irreversible damage may already have occurred. AccelRare® is our call to transform compassion into concrete action, democratizing rare disease expertise and putting the diagnostic intelligence of 50 world class specialists into the hands of every doctor in every corner of India."